<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 19, 2000
NOVAVAX, INC.
-------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-26770 22-2816046
-------- ------- ----------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation or organization) File No.) Identification No.)
8320 GUILFORD ROAD, COLUMBIA, MD 21046
-------------------------------- -----
(Address of principal executive offices) (Zip code)
(301) 854-3900
--------------
Registrant's telephone number, including area code
NOT APPLICABLE
--------------
(Former name or former address, if changed since last report)
<PAGE> 2
NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT
ITEM 5. OTHER EVENTS.
On December 19, 2000 the Company announced that King
Pharmaceuticals, Inc. has agreed to make a $25 million convertible
note investment in the Company.
A copy of the Press Release is attached hereto as Exhibit 99.1
and incorporated herein by this reference.
ITEM 7. EXHIBITS.
Exhibits.
99.1 Press Release dated December 20, 2000.
99.2 Note Purchase Agreement dated December 19, 2000 between
Novavax, Inc. and King Pharmaceuticals, Inc.
99.3 Convertible Note dated December 19, 2000 between Novavax, Inc.
and King Pharmaceuticals, Inc.
99.4 Investor Rights Agreement dated December 19, 2000 between
Novavax, Inc. and King Pharmaceuticals, Inc.
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NOVAVAX, INC.
Date: January 02, 2001 By:
------------------------------
Dennis W. Genge, Vice President
And Chief Financial Officer/Treasurer
